Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib for Refractory Rheumatoid Arthritis
NCT05805891Phase 2Recruiting
- Sponsor
- Chinese SLE Treatment And Research Group
- Start
- Dec 2023
- Primary completion
- Jun 2025
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of bortezomib in rheumatoid arthritis (RA), sponsored by Chinese SLE Treatment And Research Group. Started Dec 2023; status: recruiting.
02
Drugs
bortezomib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05805891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05805891.